Next report date
Report period
H1 2024
EPS estimate
—
Revenue estimate
129.60 MCHF
−1.50CHF
−49.98 MCHF
311.26 MCHF
13.30 M
About POLYPEPTIDE N
Sector
Industry
CEO
Juan-José Gonzalez
Website
Headquarters
Baar
Employees (FY)
1.27 K
Founded
1996
FIGI
BBG0100P02R8
PolyPeptide Group AG engages in the business of development, manufacturing, and marketing of peptide- and oligonucleotide-based compounds for use in the pharmaceutical and related research industries. It operates through the following business areas: Custom Projects, Contract Manufacturing, and Generics and Cosmetics. The Custom Projects business area includes manufacturing of custom research-grade peptides and oligonucleotides for use in pre-clinical and clinical development as well as for regulatory and scientific studies. The Contract Manufacturing business area focuses on peptides for commercial stage peptide therapeutics, at scale, in commercial batches and in accordance with current Good Manufacturing Practice (cGMP) requirements. The Generics and Cosmetics business area is involved in peptide-based generics for the human and veterinary market, produced on an industrial scale following cGMP guidelines. The company was founded in 1996 and is headquartered in Zug, Switzerland.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of PPGN is 29.55 CHF — it has increased by 2.43% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on SIX exchange POLYPEPTIDE N stocks are traded under the ticker PPGN.
POLYPEPTIDE N is going to release the next earnings report on Aug 13, 2024. Keep track of upcoming events with our Earnings Calendar.
PPGN stock is 2.78% volatile and has beta coefficient of 1.75. Check out the list of the most volatile stocks — is POLYPEPTIDE N there?
POLYPEPTIDE N revenue for the last quarter amounts to 128.77 M CHF despite the estimated figure of 126.49 M CHF. In the next quarter revenue is expected to reach 149.80 M CHF.
Yes, you can track POLYPEPTIDE N financials in yearly and quarterly reports right on TradingView.
PPGN stock has risen by 2.60% compared to the previous week, the month change is a 1.83% rise, over the last year POLYPEPTIDE N has showed a 42.20% increase.
PPGN net income for the last quarter is −16.45 M CHF, while the quarter before that showed −33.77 M CHF of net income which accounts for 51.30% change. Track more POLYPEPTIDE N financial stats to get the full picture.
Today POLYPEPTIDE N has the market capitalization of 974.25 M, it has decreased by 2.08% over the last week.
Like other stocks, PPGN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade POLYPEPTIDE N stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 27, 2024, the company has 1.27 K employees. See our rating of the largest employees — is POLYPEPTIDE N on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So POLYPEPTIDE N technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating POLYPEPTIDE N stock shows the buy signal. See more of POLYPEPTIDE N technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on POLYPEPTIDE N future price: according to them, PPGN price has a max estimate of 30.15 CHF and a min estimate of 16.85 CHF. Read a more detailed POLYPEPTIDE N forecast: see what analysts think of POLYPEPTIDE N and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. POLYPEPTIDE N EBITDA is −10.62 M CHF, and current EBITDA margin is −3.27%. See more stats in POLYPEPTIDE N financial statements.